Bortezomib (GMP)
Bortezomib (GMP) (PS-341 (GMP) ) is Bortezomib produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Bortezomib can be used for the study of multiple myeloma (MM)[2]. Bortezomib effectively inhibits TREM2 expression in tumor-associated macrophages (TAMs) [7].
Product Specifications
Product Name Alternative
PS-341 (GMP) ; LDP-341 (GMP) ; NSC 681239 (GMP)
UNSPSC
12352005
Target
Apoptosis; Autophagy; NF-κB; Proteasome; TREM receptor
Related Pathways
Apoptosis; Autophagy; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB
Field of Research
Cancer
Smiles
OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
Molecular Formula
C19H25BN4O4
Molecular Weight
384.24
References & Citations
Shipping Conditions
Room temperature
Scientific Category
GMP Small Molecules
Clinical Information
No Development Reported
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
